LINEAGE CELL THERAPEUTICS IN (LCTX): Hedge Fund Ownership & Smart Money Signals (Q4 2025)

LINEAGE CELL THERAPEUTICS IN (LCTX)

121 + Investors. Track Smart Money conviction in LCTX. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — LCTX

Based on 117 hedge funds · latest filing: 2025 Q4 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds added LCTX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

📊

High ownership — 94% of 3.0Y peak

94% of all-time peak

117 funds currently hold this stock — 94% of the 3.0-year high of 124 funds (reached 2025 Q2). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.

〰️

Stable — ownership unchanged year-over-year

fund count last 6Q

The number of hedge funds holding LCTX is almost the same as a year ago (+1 funds, +1% change). No significant rush to buy or sell — institutional backing is holding steady.

🟡

Slight buying edge — 57% buying

54 buying41 selling

Last quarter: 54 funds bought or added vs 41 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

📈

More new buyers each quarter (+9 vs last Q)

new funds entering per quarter

Funds opening a new LCTX position: 18 → 35 → 16 → 25. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔒

56% of holders stayed for 2+ years

■ 56% conviction (2yr+) ■ 19% medium ■ 26% new

65 out of 117 hedge funds have held LCTX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

📊

Peak discovery — momentum slowing

22 → 18 → 35 → 16 → 25 new funds/Q

New funds entering each quarter: 18 → 35 → 16 → 25. LCTX is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.

🏛️

Deep conviction — 65% of holders stayed 2+ years

■ 65% veterans ■ 5% 1-2yr ■ 30% new

Of 121 current holders: 79 (65%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.

✅

Strong quality — 22% AUM from major funds

22% from top-100 AUM funds

19 of 117 holders rank in the top 100 by AUM, accounting for 22% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

3.3

out of 10

Low Exit Risk

Exit risk score 3.3/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2025 Q4)	Prior (2025 Q3)	Change
Funds Holding	121	111	9.01%
13F Shares	97M	83M	16.26%
Total Value	$168M	$140M	19.3%
New Positions	25	16	+9
Increased Positions	36	24	+12
Closed Positions	14	34	-20
Reduced Positions	35	43	-8
Total Calls	2	3	-33.33%
Total Puts	2	2	-
PUT/CALL Ratio	1.0	0.67	Neutral

Metric

All 13F Filers (2025 Q4)

Prior (2025 Q3)

Change

Funds Holding

121

111

9.01%

13F Shares

97M

83M

16.26%

Total Value

$168M

$140M

19.3%

New Positions

Increased Positions

+12

Closed Positions

-20

Reduced Positions

-8

Total Calls

-33.33%

Total Puts

PUT/CALL Ratio

1.0

0.67

Neutral

Institutional Holders (2026 Q1)

121 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in LCTX. Verified SEC 13F-HR filings.

FILTER: All New Added To Reduced No Change | Overweight >5%

Top 20 institutional holders of LCTX — 2025 Q4 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Defender Capital, LLC.	3.77%	6,729,599	$10.6M
2	McMillan Office, Inc.	0.04%	216,000	$341K
3	DEFINE FINANCIAL, LLC	0.02%	20,000	$32K
4	ELCO Management Co., LLC	0.02%	20,500	$32K
5	Piscataqua Savings Bank	0.01%	12,499	$20K
6	TRUST CO OF TOLEDO NA /OH/	0.01%	83,795	$132K
7	Founders Capital Management	0.01%	16,000	$25K
8	CHAPIN DAVIS, INC.	0.01%	20,029	$32K
9	LAZARI CAPITAL MANAGEMENT, INC.	0.01%	10,500	$17K
10	Allegheny Financial Group	0.00%	20,000	$32K
11	Lafayette Investments, Inc.	0.00%	13,000	$21K
12	AssuredPartners Investment Advisors, LLC	0.00%	16,500	$25K
13	PFG Investments, LLC	0.00%	22,202	$35K
14	Pacifica Partners Inc.	0.00%	2,926	$5K
15	WOLFF WIESE MAGANA LLC	0.00%	1,000	$2K
16	Mesirow Financial Investment Management, Inc.	0.00%	30,500	$48K
17	ALBION FINANCIAL GROUP /UT	0.00%	3,043	$5K
18	COMMONWEALTH EQUITY SERVICES, LLC	0.00%	102,828	$162K
19	Private Advisor Group, LLC	0.00%	20,029	$32K
20	Farther Finance Advisors, LLC	0.00%	544	—

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — LINEAGE CELL THERAPEUTICS IN (LCTX)

What does the Smart Money Trend signal show for LCTX?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added LCTX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for LCTX?

Slight buying edge — 57% buying: Last quarter: 54 funds bought or added vs 41 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for LCTX holders?

Strong quality — 22% AUM from major funds: 19 of 117 holders rank in the top 100 by AUM, accounting for 22% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held LCTX?

56% of holders stayed for 2+ years: 65 out of 117 hedge funds have held LCTX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

LINEAGE CELL THERAPEUTICS IN (LCTX)

Smart Money Signals — LCTX

Buying streak — 1 quarter in a row

High ownership — 94% of 3.0Y peak

Stable — ownership unchanged year-over-year

Slight buying edge — 57% buying

More new buyers each quarter (+9 vs last Q)

56% of holders stayed for 2+ years

Peak discovery — momentum slowing

Deep conviction — 65% of holders stayed 2+ years

Strong quality — 22% AUM from major funds

Hedge Fund Ownership: LCTX

Market Analysis: LCTX

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: LCTX

Hedge Fund Positioning: LCTX

Statistics: LCTX

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q1)

Frequently Asked Questions — LINEAGE CELL THERAPEUTICS IN (LCTX)

Welcome to 13Foresight!